Related posts
Most Anticipated Earnings: MRE-T, PSI-T and more Canadian Companies Reporting Earnings this Week (Aug 05-09).Most Anticipated Earnings: BLDP-T, BOS-T and more Canadian Companies Reporting Earnings this Week (May 06-10)TSX slips during quiet MondayThis summary was created by AI, based on 20 opinions in the last 12 months.
Overall, the reviews on Converge Technology Solutions appear to be mixed, with some experts expressing concern over the company's performance and management, while others see potential for growth and value in the stock. The company has faced challenges with missed earnings expectations and slow growth, but there is optimism surrounding its low valuation, strong financial position, and potential for future acquisitions. The recent focus on operations, cost control, and integrating acquired companies indicates a shift in strategy that may lead to improved margins and performance in the long term.
Average target is now $5.04. Post-earnings, Scotiabank lowered its rating from $5 to $4. At less than 9X earnings it certainly can still be called cheap. Q3 results showed EPS of 12c, beating estimates of 9.5c. Revenue of $630.7M slightly missed estimates of $639.7M. EBITDA missed estimates by 14%. Guidance was mostly inline with estimates. Q3 sales fell 8.9% and we certainly would prefer to see this trend reverse. The CC did not add a whole lot. The CEO/Board transition is ahead of plan. CTS continues to return capital to shareholders (buybacks and dividends). CTS is not seeing attractive acquisitions and prefers to buyback its stock over making a mis-priced deal. With rising cash flow conversion the balance sheet is in much better shape, with net debt less than six months of cash flow now. This 'should' help the valuation multiple over time.
Unlock Premium - Try 5i Free
Company has been disappointing lately. 2020 was a good year, but since then growth has slowed. Earnings not matching expectations. Share price is cheap, but better options out there for investors. Has sold shares. Management team not meeting with investors enough.
Very high debt to equity of around 99%. ROE is -33%. Financial metrics tell him to stand aside.
(Analysts’ price target is $6.25)They don't make a lot of profit. Cut it and move on. Take a tax loss.
Owns small amount of shares. M&A has paused lately. Strategic review didn't go well. Time will tell whether business will continue to perform. Wait and see type of stock.
We continue to like CTS, and although its recent momentum has not been favourable, we believe its long-term value is still in play. It pays a small yield of 1.4%, analysts expect decent forward sales and earnings growth, albeit slightly lumpy, but its valuation reflects this, at 7X forward earnings. Its valuation is cheap, its debt levels are fine, and its free cash flow is impressive. While recent momentum has not been great, we continue to believe its valuation will re-rate as its fundamentals continue to improve.
Unlock Premium - Try 5i Free
Will see strength in the tech sector going forward. Would recommend buying if the chart begins to turn. Seeing upside in the stock.
It's done OK, but not as great as the big names. 12-month target is $6.55. Pretty widely held. Removed from the TSX Composite, so that dragged it out of some portfolios. Buy in thirds here at $4.70, $4.50, and $4.25.
Fundamentally, the story hasn't changed. Market's gone through a correction. Very inexpensive. Good play on AI, as purchases in that area are made through a company like this. Be patient. Low valuation, raised dividend, buying back stock, you'll be fine.
Hired some new expertise. 12-month price target around $6.25. If it breaks through that, there's nothing between $6.75 and $10. He's watching carefully.
Great rebound this year. Acquisition spree, overpaid, grandiose ambitions. New CFO has transformed operations. Outlook very solid. Very strong shape financially. Buying back shares, initiated dividend. Cheap at 8-9x earnings. More upside.
It missed a couple of quarters and has undergone a strategic review but has not been sold. It has stopped doing acquisitions and is focusing on operations. It has a new CFO who has a good reputation. It looks cheap, is executing, and is a potential takeover. He is looking at an $8 target.
Way better tech investments to make. Tried to sell company, didn't go anywhere, stock collapsed. Low-margin business.
Recent breakout good for momentum investors. Not at all time highs yes. Watching closely. Fairly stable up trend. Now a good time to buy.
Converge Technology Solutions is a Canadian stock, trading under the symbol CTS-T on the Toronto Stock Exchange (CTS-CT). It is usually referred to as TSX:CTS or CTS-T
In the last year, 16 stock analysts published opinions about CTS-T. 8 analysts recommended to BUY the stock. 6 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Converge Technology Solutions.
Converge Technology Solutions was recommended as a Top Pick by on . Read the latest stock experts ratings for Converge Technology Solutions.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
16 stock analysts on Stockchase covered Converge Technology Solutions In the last year. It is a trending stock that is worth watching.
On 2025-01-10, Converge Technology Solutions (CTS-T) stock closed at a price of $3.51.
It is not getting it done with a lot of execution not happening now. It is cheap but needs a private equity group to take it out and have new management. There is already anticipation of a takeout so it is risky.